Working… Menu
Trial record 55 of 143 for:    NIFEDIPINE

High Dose BAYA1040_Nifedipine: a Long Term Combination Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01294215
Recruitment Status : Completed
First Posted : February 11, 2011
Last Update Posted : June 23, 2014
Information provided by (Responsible Party):

Brief Summary:
This is a clinical study evaluating the safety and efficacy of long term administration of oral BAYA1040_Nifedipine 80 mg/day (40 mg twice daily) with other antihypertensives in patients with essential hypertension who are not at target blood pressure by the combination of BAYA1040_Nifedipine 40 mg once daily and other antihypertensives.

Condition or disease Intervention/treatment Phase
Hypertension Drug: Nifedipine (Adalat, BAYA1040) Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 72 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open Label, Long Term Study of Oral BAYA1040_CR 80 mg (40 mg Bid) in Combination With Other Antihypertensives for 52 Weeks in Patients With Essential Hypertension
Study Start Date : February 2011
Actual Primary Completion Date : November 2011
Actual Study Completion Date : June 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Nifedipine

Arm Intervention/treatment
Experimental: Arm 1 Drug: Nifedipine (Adalat, BAYA1040)
Nifedipine (Adalat, BAYA1040) 40mg twice a day (BID)

Primary Outcome Measures :
  1. Efficacy changes measured by sitting diastolic blood pressure (DBP) [ Time Frame: Up to 52 weeks ]

Secondary Outcome Measures :
  1. Efficacy changes measured by sitting systolic blood pressure (SBP) [ Time Frame: Up to 52 weeks ]
  2. Proportion of subjects achieving a target BP based on the Japanese Society of Hypertension (JSH) 2009 guidelines [ Time Frame: Up to 52 weeks ]
  3. Proportion of subjects achieving a target DBP and SBP based on JSH 2009 guidelines or a >10 mmHg reduction of DBP [ Time Frame: Up to 52 weeks ]
  4. Safety variables [ Time Frame: Up to 30 days after the last dose of study drug ]
    Adverse events, vital signs, electrocardiography (ECG), and laboratory tests were evaluated.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 20 years or older
  • Japanese male or female
  • Outpatient with essential hypertension
  • Patients who are treated with Adalat CR 40 mg od and at least one antihypertensive drug (other than Ca antagonists) for 4 weeks or more before entry in this study

Exclusion Criteria:

  • Patients whose sitting diastolic blood pressure (DBP) is 110 mm Hg or more
  • Patients with secondary hypertension or hypertensive emergency

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01294215

Layout table for location information
Ebina, Kanagawa, Japan, 243-0401
Sagamihara, Kanagawa, Japan, 252-0311
Kawaguchi, Saitama, Japan, 332-0012
Shinjuku, Tokyo, Japan, 169-0072
Sponsors and Collaborators
Layout table for investigator information
Study Director: Bayer Study Director Bayer

Additional Information:
Layout table for additonal information
Responsible Party: Bayer Identifier: NCT01294215     History of Changes
Other Study ID Numbers: 14024
First Posted: February 11, 2011    Key Record Dates
Last Update Posted: June 23, 2014
Last Verified: June 2014
Keywords provided by Bayer:
Essential hypertension
Japanese Patients
Phase III
combination study
Additional relevant MeSH terms:
Layout table for MeSH terms
Essential Hypertension
Vascular Diseases
Cardiovascular Diseases
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Vasodilator Agents
Tocolytic Agents
Reproductive Control Agents